1.Indicated for the treatment of patients with Philadelphia chromosome positive(Ph+) chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase.
2. Indicated for the treatment of pediatric patients with acute lymphoblastic leukemia(Ph+ALL) whose disease has recurred after stem cell transplant or who are resistant to interferon alpha therapy.
3. Indicated for the adults of hypereosinophilic syndrome(HES) and/or chronic eosinophilic leukemia(CEL) with FIP1L1-PDGFRα.
4. Indicated for the adults of myelodysplastic/myeloproliferative neoplasms (MDS/MPD) with platelet-derived growth factor receptors(PDGFR) gene rearrangement.
5. Indicated for the adults of aggressive systemic mastocytosis(ASM) without gene mutation of D816Vc-Kit or unknown c-Kit.
6. Indicated for the treatment of unresectable, recurred or metastatic dermatofibrosarcoma protuberans(DFSP).